S5 - E11.5 - MASH Prescribing Models & The Increasing Challenge Of Keeping Patients In Long-Term Clinical Trials
Send us a text This final conversation starts by considering prescribing models for other diseases and how they might work here, shifts to discussing the challenges of keeping a patient enrolled in a long-term clinical trial (or even participating in a trial in the first place), and moves on to the final question for the episode. The conversation picks up on the FG-21 conversation, particularly how FGF-21 might be prescribed alongside Rezdiffra. Roger Green starts by asking whether and...
21 Apr 202410min
S5 - E11.4 - More Hot MASLD Topics: Inflammation, MD columnists' Advice, FGF-21s
Send us a text This conversation sees the end of the "hot topics" discussion, followed by Michael Charlton discussing issues and excitement around the FGF-21 class. As we begin, Louise Campbell and Jörn Schattenberg speculate on ways to incorporate metrics like the Dietary Inflammation Index into multifactorial care. Michael asks whether alcohol is figured in the index, given its pro-inflammatory nature, and celebrates the fact that we can now evaluate MetALD patients as a group instead of r...
21 Apr 202410min
S5 - E11.3 - Panelists' Hot Topics: Low-Dose Aspirin, SLD Think Tank, Dietary Inflammation Index
Send us a text After Michael Charlton finishes discussing research he finds compelling, Jörn Schattenberg and Louise Campbell each describe one item they have been focusing on recently. Michael mentions the recent JAMA publication of a small, randomized controlled trial exploring the use of low-dose aspirin in biopsy-confirmed MASLD patients, which he describes as "a tremendous result." The results suggest benefits in terms of both fat fraction (PDFF) and transaminase levels. Jörn prov...
20 Apr 202413min
S5 - E11.2 - Defining Therapeutic Futility For Rezdiffra And Discussing Advances In MASLD Translational Medicine
Send us a text Michael Charlton and the Surfers discuss two issues: defining therapeutic futility for Rezdiffra and describing some advances in MASLD translational medicine. The conversation starts by continuing the topic of therapeutic futility. Louise Campbell asks Michael how he plans to determine therapeutic futility with Rezdiffra in terms of side effects or efficacy. Michael indicates that he will continue patients on Rezdiffra as long as their disease does not progress. While he...
20 Apr 202411min
S5 - E11.1 - How The Rezdiffra Approval Has Affected How One Clinic Manages MASH Patients
Send us a text In this initial conversation, Michael Charlton describes some ways that the presence of Rezdiffra has affected practices and procedures in his clinic and shares issues he and his colleagues are discussing. As the conversation begins, Michael hails Rezdiffra as proof that as a species, "we can be capable of amazing things in a good way," a drug approved by FDA to reverse fibrosis in a significant number of patients with the world's most common liver disease. From there, h...
20 Apr 202411min
S5 - E11 - Life With Rezdiffra: Early Impact On MASH Patient Treatment and MASLD Clinical Trials
Send us a text Michael Charlton joins Jörn Schattenberg, Louise Campbell, and Roger Green for a far-reaching conversation that covers ways Rezdiffra is already impacting MASH patient treatment, exciting recent studies and broader issues in clinical trial recruitment. 00:00:00 - Surf's Up: Season 5 Episode 11 Opening comments from the panel, including brief quotes taken directly from the episode. 00:02:32 - Introduction Opening comments (re)introducing listeners to Michael Charl...
18 Apr 202453min
S5 - E10 - Lessons And Insights On Using Basic EHR Data To Screen For Target MASLD Patients
Send us a text This episode is a follow-up to Season 4, Episode 5, where we met Tim Jobson. His company, Predictive Health Intelligence (PHI), takes a unique approach to identifying and monitoring MASLD patients using basic EHR data and analytics. This session explores PHI's work over the past years and considers implications for several liver-related health challenges. 00:00:00 - Surf's Up: Season 5 Episode 10 Opening comments from the panel, including brief quotes taken directly from...
15 Apr 202456min
S5 - E9.6 - From The Vault: An Earlier Look At Screening In The Clinical Care Pathway
Send us a text This conversation comes from our coverage of The EASL Congress, 2023, when Sven Francque and Ian Rowe joined Jörn Schattenberg and Roger Green to consider primary care screening at the top of the Clinical Care Pathway. The original conversation had a robust write-up: Ian starts this conversation by pointing to unmet needs in the primary care setting for disease identification. He refers to a related presentation of interest from Vincent Wong titled A clinical care pathwa...
7 Apr 202412min
